Real-World Treatment Patterns and Associated Outcomes in Patients With Resectable Early-Stage Non-Small Cell Lung...

Area of Science:

• Oncology
• Clinical Research
• Public Health

Background:

• The THASSOS-INTL study (NCT04808050) is a multinational, retrospective analysis.
• It examines treatment patterns and outcomes for early-stage non-small cell lung cancer (NSCLC) in the Asia-Pacific, Middle East, and Africa.

Purpose of the Study:

• To evaluate treatment strategies and patient outcomes in early-stage NSCLC.
• To identify trends in therapy use and survival rates.

Main Methods:

• Retrospective analysis of 755 adult patients with resectable NSCLC (Clinical Stage IA-IIIB).
• Data collected from January 1, 2013, to December 31, 2020.
• Follow-up until death, last visit, or data cut-off.

Main Results:

• Surgery was performed in 82.9% of patients; 39.1% received surgery alone.
• Adjuvant therapy was used in 51.1%, while neoadjuvant therapy was used in 21.1%.
• Three-year survival was 77.4%, with a median overall survival of 7.5 years, highest with adjuvant therapy.

Conclusions:

• Adjuvant therapy use exceeded 50%, aligning with guidelines, but neoadjuvant therapy use was suboptimal.
• Low biomarker testing rates (EGFR, PD-L1) reflect the study period predating widespread targeted/immunotherapies.
• A multidisciplinary approach is crucial for optimizing treatment decisions and improving outcomes for early-stage NSCLC patients, especially with emerging therapies.